- Population PK/PD analysis
- Nonclinical PK/PD modeling & simulation
- First-in-Human (FIH) dose estimation based on nonclinical PK/PD modeling
- Human PK/PD evaluation via early clinical trial data
- Non-Compartmental Analysis (NCA) on early clinical trial data
- Drug development consultation on clinical study design
- Pharmacometric consultation: Liaison services with bioanalytical facilities and
sponsors to ensure PK data integrity and to provide data interpretation
- Scientific report writing
- DDI Prediction
